Neogenomics Inc
NEO Nasdaq· Services-Testing Laboratories
Last close · Oct 26, 2026
$16.69
KIRA · Stoqly’s AI analyst, in plain words
- Neogenomics Inc had $727M of revenue in fiscal 2025, up 10.1% on the year before. Over five years, revenue changed +10.4% a year on average.
- Its operating margin was −15.9%, down 2.0 pts: of every 100 in sales, about −16 is left after running the business.
- Neogenomics Inc lost $108M in fiscal 2025.
- Free cash flow was −$21.8M in fiscal 2025, −3.0% of revenue.
- Neogenomics Inc owes $182M more than it holds in cash.
Market cap
$2.2B
P/E
—
Revenue
$727M
Net income
−$108M
Free cash flow
−$21.8M
Operating margin
−15.9%
Neogenomics Inc in 30 seconds · fiscal 2025
Are sales growing?
+10.1%
Yes. Sales grew 10.1% last year.
Does it make a profit?
−14.9%
No. It lost money last year.
Does profit turn into cash?
−3.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
What Neogenomics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- NEOGENOMICS INC
- CIK
- 0001077183
Neogenomics Inc · NEO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $484M | $510M | $592M | $661M | $727M |
| Revenue growth | 9.0% | 5.2% | 16.1% | 11.6% | 10.1% |
| Gross margin | 38.6% | 36.9% | 41.3% | 43.9% | 43.2% |
| Operating margin | −24.5% | −30.9% | −18.2% | −13.9% | −15.9% |
| Net income | −$8.3M | −$144M | −$88.0M | −$78.7M | −$108M |
| Net margin | −1.7% | −28.3% | −14.9% | −11.9% | −14.9% |
| Cash | |||||
| Cash from operations | −$26.7M | −$66.0M | −$2.0M | $7.0M | $5.2M |
| Capital expenditure | $64.1M | $30.9M | $28.8M | $41.1M | $27.0M |
| Free cash flow | −$90.9M | −$96.9M | −$30.7M | −$34.0M | −$21.8M |
| FCF margin | −18.8% | −19.0% | −5.2% | −5.2% | −3.0% |
| Share count change | 7.3% | 3.5% | 1.0% | 0.9% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $515M | $263M | $342M | $367M | $160M |
| Debt incl. finance leases | $534M | $535M | $538M | $541M | $342M |
| Shareholders' equity | $1.1B | $998M | $942M | $902M | $837M |
| Current ratio | 7.8x | 6.7x | 6.2x | 2.0x | 4.3x |
| Interest coverage | −14.4x | −20.8x | −15.6x | −13.9x | −30.9x |
| Returns and quality | |||||
| Return on capital | −8.3% | −9.8% | −7.5% | −6.8% | −9.0% |
| Return on equity | −0.9% | −13.7% | −9.1% | −8.5% | −12.4% |
| Return on tangible equity | −6.0% | −215.3% | −192.7% | −197.3% | −420.5% |
| Piotroski F-score | 1 | 2 | 4 | 5 | 5 |
| Altman Z'' | 3.2 | 2.4 | 2.4 | 1.4 | 1.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
4 insiders
Of sales under plans
67%
$0.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neogenomics Inc · NEO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $16.69 a share, the company is worth $2.2B.
Source: SEC EDGAR XBRL filings (CIK 0001077183). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.